A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(28 sites)

United States

Yale University School of Medicine /ID# 278181, New Haven, Connecticut

Ocala Oncology Center /ID# 278269, Ocala, Florida

Moffitt Cancer Center /ID# 277573, Tampa, Florida

Fort Wayne Medical Oncology And Hematology /ID# 277336, Fort Wayne, Indiana

University Hospitals Cleveland Medical Center /ID# 277556, Cleveland, Ohio